Skip to content

Efficacy and Safety of Oliceridine versus Remifentanil for Analgesia in ICU Patients After Abdominal Surgery: A Randomized Controlled Trial

Efficacy and Safety of Oliceridine versus Remifentanil for Analgesia in ICU Patients After Abdominal Surgery: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122354
Enrollment
Unknown
Registered
2026-04-13
Start date
2026-04-13
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Postoperative Pain

Interventions

Experimental Group:In the study group, 10 mg of oliceridine injection was diluted in 40 ml of normal saline to prepare a 50 ml solution with a concentration of 0.2 mg/ml. An initial loading dose of 1.
Control Group:In the control group, 2 mg of remifentanil was diluted in 50 ml of normal saline to prepare a solution with a concentration of 40 µg/ml. An initial loading dose of placebo (normal saline

Sponsors

Tianjin Medical University General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 80 years old 2. Patients who need mechanical ventilation after abdominal surgery and are transferred to the ICU

Exclusion criteria

Exclusion criteria: 1. Severe cardiac dysfunction (NYHA IV grade), abnormal liver function (Child-Pugh C grade), abnormal kidney function (preoperative dialysis was performed), or ASA classification >= IV grade; 2. Allergy to opioid drugs; 3. Pregnant or lactating patients; 4. Severe hemodynamic instability (NE requirement > 0.5 µg/kg/min to maintain MAP >= 65 mmHg, or frequent malignant arrhythmias); 5. Chronic pain treated with long-term analgesic drugs; 6. QT interval on electrocardiogram: > 450 ms for males, > 470 ms for females; 7. Need to use muscle relaxants or deep sedation (RASS -5 to -3); 8. Patients with communication disorders; 9. Other situations deemed inappropriate for participation in the study by researchers or supervising doctors.

Design outcomes

Primary

MeasureTime frame
The percentage of time within the target analgesic level (CPOT <=3) relative to the total study drug administration time.;

Secondary

MeasureTime frame
Proportion of Patients with Sustained Target Analgesia;Time to onset and incidence rate of rebound pain;The proportion of patients receiving rescue analgesic medication.;

Countries

China

Contacts

Public ContactKeliang Xie

Tianjin Medical University General Hospital

xiekeliang2009@hotmail.com+86 153 3211 2099

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026